Faron Pharmaceuticals (FARN) H2 2024 earnings summary

Executive summary

• 2024 marked a transformative year with strengthened financials, new leadership, and significant clinical progress, including bexmarilimab's 80% response rate and 13.4 months survival in r/r MDS, far exceeding standard care.

• Major milestones included €35.5M raised, narrowed loss to €26M, and management overhaul with new CEO, CFO, CMO, and Chairman, plus a renewed scientific advisory board.

• Bexmarilimab advanced with strong phase 1 and 2 results, receiving FDA Fast Track, MHRA Innovation Passport, and EMA orphan designation.

• Enrollment for phase 2 completed; top-line results expected in April 2025, with detailed data to follow at major conferences.

• Patent filed for use of soluble Clever-1 in autoimmune and inflammatory diseases, expanding the pipeline.

Financial highlights

• €35.5M (EUR 35.5 million) gross raised in 2024, with year-end cash at €9.5M, up from €6.9M in 2023.

• Loss for 2024 was €26M (EUR -25.9 million), improved from €31M (EUR -30.9 million) in 2023.

• Net assets at year-end were negative €9.8M, improved from negative €15.2M prior year.

• February 2025 private placement raised €12M, nearly two times oversubscribed.

• R&D expenses decreased to EUR 11.7M; G&A expenses fell to EUR 6.9M.

Outlook and guidance

• Awaiting phase 2 top-line results in April 2025, with detailed data in May/June and regulatory feedback by end of Q2.

• Planning for end-of-phase 2 FDA meeting and phase 3 trial design, with first phase 3 patient expected in 6–8 months post-approval.

• Directors estimate current cash plus €12M raised in Feb 2025 will fund operations into Q3 2025; additional financing is being sought.

• Anticipated increase in cash spend towards year-end as phase 3 and solid tumor trials begin.

• Focus remains on advancing bexmarilimab through pivotal studies and regulatory engagement.